Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: Evidence for a noninvasive treatment of high-grade dysplasia

Journal of Thoracic and Cardiovascular Surgery

Volumn 145, Issue 2, 2013, Pages 531-538

  Inge, Landon J ^a   Fowler, Aaron J ^a   Paquette, Kimberly M ^b   Richer, Amanda L ^a   Tran, Nhan ^b   Bremner, Ross M ^a  

^a ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DASATINIB; PROTEIN P27; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CELL CYCLE; CELL CYCLE ARREST; CELL LINE; DYSPLASIA; ENZYME ACTIVATION; ESOPHAGUS BIOPSY; FLOW CYTOMETRY; GROWTH INHIBITION; HIGH GRADE DYSPLASIA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; NON INVASIVE PROCEDURE; PRECANCER; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

APOPTOSIS; BARRETT ESOPHAGUS; BIOPSY; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FLOW CYTOMETRY; HUMANS; PHOSPHORYLATION; PRECANCEROUS CONDITIONS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; THIAZOLES;

EID: 84872348667     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2012.10.041     Document Type: Article

References (25)

1. B.J. Reid, X. Li, P.C. Galipeau, and T.L. Vaughan Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis Nat Rev Cancer 10 2010 87 101
2. H. Pohl, and H.G. Welch The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence J Natl Cancer Inst 97 2005 142 146
3. B.J. Reid, D.S. Levine, G. Longton, P.L. Blount, and P.S. Rabinovitch Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets Am J Gastroenterol 95 2000 1669 1676
4. F. Yousef, C. Cardwell, M.M. Cantwell, K. Galway, B.T. Johnston, and L. Murray The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis Am J Epidemiol 168 2008 237 249
5. S.J. Spechler, P. Sharma, R.F. Souza, J.M. Inadomi, and N.J. Shaheen American Gastroenterological Association medical position statement on the management of Barrett's esophagus Gastroenterology 140 2011 1084 1091
6. P.C. Galipeau, X. Li, P.L. Blount, C.C. Maley, C.A. Sanchez, and R.D. Odze NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma PLoS Med 4 2007 e67
7. C.L. Chang, P. Lao-Sirieix, V. Save, G. De La Cueva Mendez, R. Laskey, and R.C. Fitzgerald Retinoic acid-induced glandular differentiation of the oesophagus Gut 56 2007 906 917
8. L.N. Puls, M. Eadens, and W. Messersmith Current status of SRC inhibitors in solid tumor malignancies Oncologist 16 2011 566 578
9. S. Iravani, H.Q. Zhang, Z.Q. Yuan, J.Q. Cheng, R.C. Karl, and R. Jove Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia Hum Pathol 34 2003 975 982
10. J. Jankowski, G. Coghill, D. Hopwood, and K.G. Wormsley Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus Gut 33 1992 1033 1038
11. S. Kumble, M.B. Omary, C.A. Cartwright, and G. Triadafilopoulos Src activation in malignant and premalignant epithelia of Barrett's esophagus Gastroenterology 112 1997 348 356
12. S.P. Singh, J. Lipman, H. Goldman, F.H. Ellis, L. Aizenman, and M.G. Cangi Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma Cancer Res 58 1998 1730 1735
13. I. Chu, J. Sun, A. Arnaout, H. Kahn, W. Hanna, and S. Narod p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2 Cell 128 2007 281 294
14. M.K. James, A. Ray, D. Leznova, and S.W. Blain Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity Mol Cell Biol 28 2008 498 510
15. M.C.A. Palanca-Wessels, A. Klingelhutz, B.J. Reid, T.H. Norwood, K.E. Opheim, and T.G. Paulson Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model Carcinogenesis 24 2003 1183 1190
16. R.E. Kosoff, K.L. Gardiner, L.M. Merlo, K. Pavlov, A.K. Rustgi, and C.C. Maley Development and characterization of an organotypic model of Barrett's esophagus J Cell Physiol 227 2012 2654 2659
17. L.J. Inge, K.D. Coon, M.A. Smith, and R.M. Bremner Expression of LKB1 tumor suppressor in non-small cell lung cancer determines sensitivity to 2-deoxyglucose J Thorac Cardiovasc Surg 137 2009 580 586
18. S. Fleige, V. Walf, S. Huch, C. Prgomet, J. Sehm, and M.W. Pfaffl Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR Biotechnol Lett 28 2006 1601 1613
19. I.M. Chu, L. Hengst, and J.M. Slingerland The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy Nat Rev Cancer 8 2008 253 267
20. C. Craig, R. Wersto, M. Kim, E. Ohri, Z. Li, and D. Katayose A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells Oncogene 14 1997 2283 2289
21. A. Sgambato, Y.J. Zhang, M. Ciaparrone, J.W. Soh, A. Cittadini, and R.M. Santella Overexpression of p27Kip1 inhibits the growth of both normal and transformed human mammary epithelial cells Cancer Res 58 1998 3448 3454
22. B. St Croix, C. Sheehan, J.W. Rak, V.A. Florenes, J.M. Slingerland, and R.S. Kerbel E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1) J Cell Biol 142 1998 557 571
23. X. Wang, M. Gorospe, Y. Huang, and N.J. Holbrook p27Kip1 overexpression causes apoptotic death of mammalian cells Oncogene 15 1997 2991 2997
24. Y. Katayose, M. Kim, A.N. Rakkar, Z. Li, K.H. Cowan, and P. Seth Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27 Cancer Res 57 1997 5441 5445
25. J. Cuzick, F. Otto, J.A. Baron, P.H. Brown, J. Burn, and P. Greenwald Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement Lancet Oncol 10 2009 501 507